Healthcare ❯ Pharmaceuticals

Obesity Treatment

Wegovy GLP-1 Drugs Weight Loss Drugs Novo Nordisk GLP-1 Medications Drug Development Weight Management Diabetes Treatment Clinical Trials Injectable Medications Medication Discontinuation Insurance Coverage CT-388 Zepbound Medication Tirzepatide Biotechnology GLP-1 Agonists Weight Loss Mechanism Semaglutide Employer Coverage Programs Mounjaro Medicare Programs Eli Lilly Weight Loss Medications GLP-1 Hormones GLP-1 Therapies Zepbound GLP-1 Receptor Agonists Weight-loss Drugs GLP-1 Injections Competitors

UK Clears Oral Wegovy and Foundation Pledges Europe Research Cash

Regulator approval and a multi‑year foundation fund signal broader access to a pill option and renewed institutional support for cardiometabolic drug discovery.

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

GLP-1 Weight-Loss Draws Harsher Stigma Than Lifestyle Change, Study Finds

Eli Lilly Unveils Employer Connect, Offering Zepbound to Employers at a Uniform $449 Net Price

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone